All stock lists
Allogene Therapeutics, Inc. (NASDAQ:ALLO)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.23-0.02 (-1.60%)
Insider Score
––Not scored
ALLO Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
ALLO Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 4.64 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | -100.00 % |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 4.64 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 20.84 M | 14.09 M | 13.77 M | 13.74 M | 14.28 M | 14.99 M |
| R&D Expense | 30.72 M | 32.00 M | 28.63 M | 31.16 M | 40.16 M | 50.20 M |
| Operating Expenses | 51.56 M | 46.09 M | 42.40 M | 44.90 M | 56.82 M | 65.19 M |
| Operating Income | -46.92 M | -46.09 M | -42.40 M | -44.90 M | -56.82 M | -65.19 M |
| Pretax Income | -42.68 M | -42.61 M | -38.81 M | -41.40 M | -50.94 M | -59.73 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -42.68 M | -42.61 M | -38.81 M | -41.40 M | -50.94 M | -59.73 M |
| EPS (Basic) | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 |
| EPS (Diluted) | -0.13 | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 |
| Shares Outstanding | 328.93 M | 240.29 M | 220.62 M | 222.04 M | 218.93 M | 215.36 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.